Compare SLAI & BGLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
SOLAI Limited American Depositary Shares (each representing one hundred (100) Class A Ordinary Shares)
Current Price
Current Price
| Metric | SLAI | BGLC |
|---|---|---|
| Founded | 2001 | 2017 |
| Country | United States | Malaysia |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.5M | 10.1M |
| IPO Year | N/A | N/A |
| Metric | SLAI | BGLC |
|---|---|---|
| Price | $1.06 | $3.63 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 929.5K | 10.5K |
| Earning Date | 02-27-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $24,209,000.00 | $9,465,006.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 2.21 |
| 52 Week Low | $0.63 | $2.01 |
| 52 Week High | $8.07 | $15.60 |
| Indicator | SLAI | BGLC |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 31.92 |
| Support Level | N/A | $3.69 |
| Resistance Level | N/A | $3.89 |
| Average True Range (ATR) | 0.00 | 0.14 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 0.00 | 9.43 |
SOLAI Ltd is a technology-driven cryptocurrency infrastructure company. It is expanding from its foundation in crypto mining to build a blockchain-based ecosystem spanning AI, stablecoins, and payment infrastructure, and Solana treasury and staking operations supporting use cases across institutional settlement, commerce, consumer payments, and AI-native agent transactions. The group is leveraging its blockchain and data infrastructure expertise, aiming to enhance on-chain efficiency and expand participation across Solana and other blockchain ecosystems.
BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.